Interleukin-6 Inhibitors

Immunosuppressive agents which inhibit the action of INTERLEUKIN-6.

Also Known As:

Agents, Anti-IL-6; Agents, Anti-IL6; Agents, Anti-Interleukin-6; Anti IL 6 Agents; Anti IL6 Agents; IL 6 Inhibitors; Inhibitors, IL-6; Inhibitors, Interleukin-6; inhibitors, IL6; Anti-IL-6 Agents; Anti-IL6 Agents; Anti-Interleukin-6 Agents; IL-6 Inhibitors; IL6 inhibitors

Networked: 147 relevant articles (17 outcomes, 26 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Chemical Actions and Uses
- Pharmacologic Actions: 160
  - Physiological Effects of Drugs: 1
    - Immunologic Factors: 7984
      - Immunosuppressive Agents: 10145
        Interleukin-6 Inhibitors: 147

Experts

1.	Sinha, Pranay: 3 articles (12/2021 - 10/2020)
2.	Atzeni, Fabiola: 3 articles (01/2021 - 06/2019)
3.	Bechman, Katie: 2 articles (07/2022 - 01/2021)
4.	Norton, Sam: 2 articles (07/2022 - 01/2021)
5.	Yates, Mark: 2 articles (07/2022 - 01/2021)
6.	Linas, Benjamin P: 2 articles (12/2021 - 10/2020)
7.	Assoumou, Sabrina A: 2 articles (01/2021 - 10/2020)
8.	Bielick, Catherine G: 2 articles (01/2021 - 10/2020)
9.	La Corte, Laura: 2 articles (01/2021 - 08/2020)
10.	Sagar, Manish: 2 articles (01/2021 - 10/2020)

Related Diseases

1.	COVID-19 11/05/2021 - "Interleukin-6 inhibitors showed promising results in observational trials of patients with coronavirus disease 2019 (COVID-19). " 01/01/2022 - "To assess the efficacy of IL-6 inhibitors compared to standard of care (SOC) in COVID-19 patients. " 12/01/2022 - "Recently, randomized open-label platform trials have found that IL-6 inhibitors have a beneficial effect on mortality in severe COVID-19. " 01/01/2022 - "Randomized control trials (RCTs) comparing IL-6 inhibitors to SOC in hospitalized COVID-19 patients were deemed eligible. " 01/01/2022 - "Interleukin-6 inhibitors reduce mortality in coronavirus disease-2019: An individual patient data meta-analysis from randomized controlled trials."
2.	Arthritis (Polyarthritis) 01/01/2019 - "Virtual Screening of IL-6 Inhibitors for Idiopathic Arthritis." 01/01/2012 - "Extension studies of the use of TCZ in systemic juvenile inflammatory arthritis have confirmed the long-term efficacy of the drug in this illness, while studies on the use of TCZ and other IL-6 inhibitors in spondyloarthropathies has been less encouraging. " 01/01/2022 - "Interleukin (IL)-1 inhibitors are largely employed in patients with Still's disease; in cases with refractory arthritis, IL-6 inhibitors have shown to be effective on articular inflammatory involvement. " 01/01/2017 - "These preclinical findings may provide insight into why patients with arthritis being treated with IL-6 inhibitors develop new onset psoriasis and why IL-6 blockade for the treatment of psoriasis has not been clinically effective." 05/01/2013 - "Systemic juvenile idiopathic arthritis (JIA) is characterized by fevers, rash, and arthritis, for which interleukin-1 (IL-1) and IL-6 inhibitors appear to be effective treatments. "
3.	Neoplasms (Cancer) 11/03/2023 - "IL-6 inhibitors were preferentially prescribed in patients with ML versus those with other malignancies. " 04/01/2013 - "This survey aims to provide an updated account of why IL-6 inhibitors are shaping up to become an important class of drugs potentially useful in the treatment of ailments and in particular in inflammation and cancer. " 11/01/2014 - "In addition we discuss the role of IL-6 in diseases with inflammatory background and cancer and also the therapeutic applications of anti-IL-6 agents. " 09/01/2009 - "Our results show that treatment with a combination of IL6 and VEGF inhibitors brings synergistic antitumoral benefit and reduces global activity of major pathways of cell survival, proliferation and invasiveness in remaining tumor cells that may be induced by using VEGF or IL6 inhibitors alone." 03/15/2015 - "Clinically registered IL6 inhibitors include siltuximab, an anti-IL6 mAb, and tocilizumab, an anti-IL6R mAb. In various cancers, in particular plasma cell cancers, large randomized trials showed no efficacy of IL6 inhibitors, despite a full inhibition of CRP production in treated patients in vivo, the numerous data showing an involvement of IL6 in these diseases, and initial short-term treatments demonstrating a dramatic inhibition of cancer cell proliferation in vivo. "
4.	Castleman Disease (Castleman's Disease) 12/01/2023 - "Treatment options for idiopathic multicentric Castleman disease (iMCD) are currently limited, especially for patients who do not respond or are resistant to interleukin-6 inhibitors. " 10/01/2021 - "In the case with symptomatic unresectable unicentric Castleman's disease treatment with anti-IL-6 agents should be considered." 12/11/2020 - "Interleukin 6 (IL-6) inhibitors are the first-line treatment for idiopathic multicentric Castleman disease (iMCD); however, there is no established treatment for cases that are resistant to IL-6 inhibitors. " 01/01/2020 - "Erythropoiesis-stimulating agents may be administered to patients with chronic kidney disease, whereas anti-IL-6 agents may be beneficial for anemic patients with rheumatoid arthritis and idiopathic multicentric Castleman disease."
5.	Pneumonia (Pneumonitis) 10/01/2022 - "However, after adjusting for covariates, this study suggests that the initiation of IL-6 inhibitors in patients with early COVID-19 pneumonitis before progression to the ICU may be associated with improved clinical status." 10/26/2021 - "Efficacy and safety of IL-6 inhibitors in patients with COVID-19 pneumonia: a systematic review and meta-analysis of multicentre, randomized trials." 01/01/2023 - "IL-6 inhibitors for critically ill patients with SARS-CoV-2 pneumonia: a suitable treatment for everyone or only for a few?" 01/01/2022 - "Moreover, during the early and late infection phases, Th2 cytokine expression and Stat3 and IL-6 signaling were persistently enhanced and myeloid macrophage cells were notably enriched in host lung, and administration of Stat3 and IL-6 inhibitors (C188-9 and LMT-28) attenuated AC infection-induced acute pneumonia in mice. " 07/01/2021 - "Keywords included "COVID-19,""coronavirus,""SARS-CoV-2,""sepsis,""pneumonia,""cytokine storm,""cytokine release syndrome,""IL-6 inhibitors," and "tocilizumab," as exact phrases, and a combination of subject headings according to databases syntax. "

Related Drugs and Biologics

1.	Interleukin-6 (Interleukin 6)
2.	tocilizumab (atlizumab)
3.	Cytokines
4.	siltuximab
5.	Interleukin-1 (Interleukin 1)
6.	sarilumab
7.	Dexamethasone (Maxidex)
8.	Interleukins
9.	Hematinics
10.	Janus Kinase Inhibitors

Related Therapies and Procedures

1.	Therapeutics
2.	Biological Therapy
3.	Artificial Respiration (Mechanical Ventilation)
4.	Complementary Therapies (Alternative Medicine)
5.	Hemoperfusion